Thursday 8 February 2018

Psoriasis Treat with Anti-tumor Necrosis Factor-Alpha

#Anti-tumor necrosis factor-α (anti-TNF) agents are used to treat different autoimmune conditions. Etanercept and Adalimumab are examples of this class of medications used for the treatment of Psoriasis. The FDA released a review in 2003 of clinical trials using anti-TNF agents and reported a relative risk for lymphoma ranging from 2.3 to 6.4. In 2005, a randomized placebo-controlled trial of Etanercept vs. placebo in patients with Wegener’s Granulomatosis found a statistically significant increase in solid malignancies in the experimental arm. Observational studies, several randomized clinical trials and the subsequent meta-analysis has emerged with conflicting results. A case of three synchronous malignancies (diffuse large B-Cell lymphoma involving heart, multiple myeloma, and invasive ductal carcinoma of breast) presenting during the use of anti-TNF agents (Etanercept and Adalimumab) for psoriasis and review current literature focused on the association of this therapeutic modality and malignancies. One must remain cautious about the risk of malignancy with anti-TNF compounds, ensuring age-appropriate cancer screening and considering avoidance in patients with proved or suspected genetic predisposition for cancer.#

No comments:

Post a Comment